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Fig 1. Giant cellulitis-like Sweet syndrome. Initial
presentation with erythematous, edematous, indurated
papules and confluent plaques on the right back
(superior) and buttock (inferior; intergluteal cleft marked
by arrow).
Fig 2. Giant cellulitis-like Sweet syndrome pathology.
Prominent papillary dermal edema (top arrow) with
abundant dermal neutrophils (bottom arrow).
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Letters e95plaques with bullous characteristics. Histopathology
revealed classic findings of Sweet syndrome. Two
patients were found to have an underlying
malignancy (multiple myeloma or breast cancer);
the other patient had no identified malignancy or
autoimmune disease.
To our knowledge, an extensive cellulitic
presentation of Sweet syndrome has only been
described in the 3 patients mentioned here. Like in
these cases, our patient had severe widespread
eruption of giant cellulitis-like plaques and was
morbidly obese. However, to date, no malignancies
have been identified in our patient. Because
Sweet syndrome may herald onset or recurrence
of malignancy,1,3 routine screenings and close
follow-up are recommended. Our patient had classicOpen access under CC BY-NC-ND license.
Open access under CC BY-NC-ND license.Sweet syndrome in the setting of precedent
bacteremia and inflammatory diseases (sicca
syndrome and PBC), yet she presented with unusual
giant cellulitis-like features. It is likely that giant
cellulitis-like Sweet syndromemay be an uncommon
clinical presentation for the different variants of
Sweet syndrome and may not be restricted to the
malignancy type.
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Cutaneous polyarteritis nodosa presenting as a
solitary blue toe
To the Editor: A woman in her 30s with a history of
Crohn disease, quiescent on mesalamine, presented
with a 1-year history of mild purple discoloration of
the left great toe, which progressed to painful,
burning nodules limiting movement of the digit.
Her symptoms did not fluctuate with changingOpen access under CC BY-NC-ND license.
Fig 1. Cutaneous polyarteritis nodosa presenting as a
solitary blue toe. Plantar side view of the left great toe
reveals edema and violaceous nodularity with collarettes
of thick scale and changes from the previous biopsy.
Fig 2. Cutaneous polyarteritis nodosa presenting as a
solitary blue toe. Histopathologic specimen reveals a
neutrophilic infiltrate obliterating a medium-sized blood
vessel wall in the deep dermis consistent with a medium
vessel vasculitis. (Hematoxylin-eosin stain; original magni-
fication: 320.)
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e96 Letterstemperatures. She smoked less than 1 pack of
cigarettes daily, but denied alcohol or drug
use. Her only other medication was paroxetine.
Numerous oral antibiotics and antifungals were pre-
viously ineffective. Prior arterial Doppler ultrasound
was normal; magnetic resonance imaging demon-
strated chronic degenerative arthritic changes.
Physical examination demonstrated multiple ten-
der subcutaneous nodules of the left hallux with
background violaceous discoloration and edema
limited to the toe (Fig 1). She was afebrile. Feet
were warm with intact sensation and pulses. Punch
biopsy showed medium vessel vasculitis (Fig 2)
consistent with polyarteritis nodosa (PAN). Tissue
cultures were negative. Complete blood count, com-
plete metabolic panel, urinalysis, antinuclear anti-
body, rheumatoid factor, complements III/IV,
human immunodeficiency virus, and hepatitis
panels were normal. Prednisone 40 mg daily was
initiated with disease resolution, but pain and edema
returned at the end of the 6-week taper. Ibuprofen
600 mg every 6 hours was initiated with
improvement.
We present a case of cutaneous polyarteritis
nodosa (cPAN) presenting as a solitary, painful,
violaceous toe. Blue toe syndrome (BTS), named
for the physical finding of a violaceous toe in
the absence of trauma, cold-induced injury, orgeneralized cyanosis, has numerous etiologies
including emboli, thromboses, vasoconstriction, in-
fections, and inflammatory disorders.1 Importantly,
vasculitis can lead to BTS, including a case of
granulomatosis with polyangiitis presenting as a
single, tender, violaceous toe 5 months before the
onset of any systemic symptoms.2
cPAN, considered a benign variant of polyar-
teritis nodosa (PAN), is frequently seen in associ-
ation with inflammatory disorders, infections, and
medications.3 It often presents as tender subcu-
taneous nodules on the lower extremities, with
associated ulceration, livedo reticularis, petechiae,
purpura, digital necrosis, and autoamputation.
Women are commonly affected with a peak
incidence in middle age.3 cPAN typically remains
localized to the skin, follows a chronic, relapsing
and remitting course, and, conventionally, does
not progress to systemic PAN. If present, extrac-
utaneous manifestations (arthralgias, myalgias,
neuropathy) should remain localized to the region
of affected skin.3
Inflammatory bowel disease has been reported
in approximately 6% of cPAN cases,3 generally
precedes the cPAN diagnosis, and is more likely
associated with Crohn disease (CD) than ulcerative
colitis.3,4 Flare in one disease does not predict poor
control in the other.4 Since the initial report in 1970,
fewer than 25 cases of cPAN associated with CD
have been reported.3-5 Most recently, a report of 2
women with CD presented with subcutaneous
nodules, edema, livedo reticularis, and Raynaud
type symptoms. One woman had longstanding,
quiescent CD before onset of cPAN, which
required cyclophosphamide and ultimately led to
amputation of a toe; the second had a banal cPAN
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with onset of symptoms around the time of her
CD diagnosis. As in our patient, cPAN is generally
responsive to corticosteroids.3,4 Nonsteroidal
anti-inflammatory medications may be useful for
prevention and treatment of mild flares and were
successfully employed in our patient.
We present an instructive case of cPAN pre-
senting as a solitary blue toe to make clinicians
aware of this unusual presentation in order to
facilitate initiation of appropriate work-up and
therapy.
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Major response to vemurafenib in patient with
severe cutaneous Langerhans cell histiocytosis
harboring BRAF V600E mutation
To the Editor: We report the case of a female patient
in her 90s with a history of age-related macular
degeneration and pulmonary embolism. In 2011, she
presented with pruritic, erythematous, confluent,
maculopapular skin lesions located on the trunk,
inframammary fold, groin, and genital and perianal
areas. Histology of a skin biopsy revealed a mono-
nuclear cell infiltrate that was morphologically and
phenotypically consistent with Langerhans cellhistiocytosis (LCH) expressing CD1a and S100-
protein by immunohistochemistry. A body
computed tomography scan showed no visceral
involvement, the patient had no exophthalmos or
diabetes insipidus, and laboratory tests related to
LCH secondary localizations were normal (eg, in-
flammatory and hepatic markers, hemogram).
Subsequently, a diagnosis of single system cuta-
neous LCH was established.
Topical and systemic corticosteroid treatments
failed to elicit any clinical improvement as first-line
treatment, and the patient was suffering from chronic
and severe pruritus and pain, affecting her quality of
life that declined significantly. A second line of
systemic treatment with thalidomide was initiated
but was quickly discontinued because the patient
experienced minor clinical response with major side
effects such as dizziness, asthenia, and impaired
coordination.
Recently, she experienced a severe new flare of
her disease with multiple papulonodular lesions in
the same skin areas (Fig 1, before). The patient
complained of major pain and had suicidal ideation
related to her intolerable skin discomfort. No ex-
tracutaneous involvement was found, and a new
biopsy confirmed the diagnosis of widespread single
system cutaneous LCH (Fig 2, A-C). In conjunction
with this finding, the DNA from the biopsy was
extracted and a pyrosequencing analysis revealed a
BRAF V600E mutation, as expected for up to 57% of
LCH cases.1
After a multidisciplinary consultation, she was
started on a third-line vemurafenib treatment, (960
mg orally twice a day) immediately after obtaining
written informed consent.
Vemurafenib induced a major clinical improve-
ment in the first days of treatment. The patient was
seen for follow-up 3 weeks after vemurafenib
introduction and showed indisputable regression of
her cutaneous lesions. Moreover, histopathologic
and immunohistochemical studies confirmed the
clinical response, in that a new biopsy revealed the
absence of remaining cells expressing LCH markers
(Fig 2, D and E). After the third month of treatment,
the clinical response remained stable and after 6
months of vemurafenib, only scar tissue was notice-
able (Fig 1, after).
Vemurafenib is an anti-BRAF targeted therapy
approved for the treatment of metastatic unresect-
able melanoma with V600 mutations; sensitivity to
this molecule was recently demonstrated for BRAF
mutated non-LCH (ie, CD1- negative Erdheim-
Chester disease).2 Here we report a major clinical
response to vemurafenib for refractory, widespread,
skin-limited, pure LCH carrying the BRAF V600E
